Poland · Delayed Price · Currency is PLN Bioceltix Statistics
Total Valuation
Bioceltix has a market cap or net worth of PLN 403.31 million. The enterprise value is 379.77 million.
| Market Cap | 403.31M |
| Enterprise Value | 379.77M |
Important Dates
The last earnings date was Tuesday, April 28, 2026.
| Earnings Date | Apr 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Bioceltix has 4.92 million shares outstanding. The number of shares has increased by 10.06% in one year.
| Current Share Class | 4.92M |
| Shares Outstanding | 4.92M |
| Shares Change (YoY) | +10.06% |
| Shares Change (QoQ) | +6.04% |
| Owned by Insiders (%) | 7.43% |
| Owned by Institutions (%) | 25.26% |
| Float | 3.83M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 14.94 |
| P/TBV Ratio | 14.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -25.00 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -46.44% and return on invested capital (ROIC) is -28.64%.
| Return on Equity (ROE) | -46.44% |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | -28.64% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | 9.78% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -370,502 |
| Employee Count | 41 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -15,380 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.27% in the last 52 weeks. The beta is 1.01, so Bioceltix's price volatility has been similar to the market average.
| Beta (5Y) | 1.01 |
| 52-Week Price Change | -29.27% |
| 50-Day Moving Average | 81.23 |
| 200-Day Moving Average | 89.08 |
| Relative Strength Index (RSI) | 45.73 |
| Average Volume (20 Days) | 5,896 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -15.27M |
| Pretax Income | -15.21M |
| Net Income | -15.19M |
| EBITDA | -14.58M |
| EBIT | -15.27M |
| Earnings Per Share (EPS) | -3.04 |
Balance Sheet
The company has 23.95 million in cash and 405,023 in debt, with a net cash position of 23.55 million or 4.78 per share.
| Cash & Cash Equivalents | 23.95M |
| Total Debt | 405,023 |
| Net Cash | 23.55M |
| Net Cash Per Share | 4.78 |
| Equity (Book Value) | 27.00M |
| Book Value Per Share | 5.48 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | -11.95M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 691,248 |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Bioceltix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.06% |
| Shareholder Yield | -10.06% |
| Earnings Yield | -3.77% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |